ArticleInternational journal of biomaterials2016
Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin.
Article in International journal of biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04646109 (The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.Fundamental & clinical pharmacology · 2021Pooled it
- Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.The Journal of antibiotics · 2020Pooled it
- Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.BMC infectious diseases · 2021Trial
- Enhancing Intracellular Uptake of Ivermectin through Liposomal Encapsulation.AAPS PharmSciTech · 2025Article
- Article
- Delivery and adjuvant: liposomes for SARS-CoV-2 vaccines.Biotechnologia · 2025Review
- Formulation and Ex Vivo Evaluation of Ivermectin Within Different Nano-Drug Delivery Vehicles for Transdermal Drug Delivery.Pharmaceutics · 2024Article
- Vector-Transmitted Flaviviruses: An Antiviral Molecules Overview.Microorganisms · 2023Review
- Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.International journal of molecular sciences · 2023Review
- Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties.International journal of pharmaceutics · 2022Article
- COVID-19 and Ivermectin: Potential threats associated with human use.Journal of molecular structure · 2021Article
- A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Regression of bovine cutaneous papillomas via ivermectin-induced immunostimulant and oxidative stress.Journal of advanced veterinary and animal research · 2021Article
- Use of nanotechnology in combating coronavirus.3 Biotech · 2021Review
- The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.International journal of molecular sciences · 2021Review
- Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.Advanced nanobiomed research · 2021Article
- Natural Compounds With Antimicrobial and Antiviral Effect and Nanocarriers Used for Their Transportation.Frontiers in pharmacology · 2021Review
- Harnessing biomaterials for therapeutic strategies against COVID-19.Emergent materials · 2021Review
- Advances in Antiviral Material Development.ChemPlusChem · 2020Article
- Ivermectin: Potential Role as Repurposed Drug for COVID-19.The Malaysian journal of medical sciences : MJMS · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA virus infections can lead to the onset of severe diseases such as fever with haemorrhage, multiorgan failure, and mortality. The emergence and reemergence of RNA viruses continue to pose a significant public health threat worldwide with particular attention to the increasing incidence of flaviviruses, among others Dengue, West Nile Virus, and Yellow Fever viruses. Development of new and potent antivirals is thus urgently needed. Ivermectin, an already known antihelminthic drug, has shown potent effects in vitro on Flavivirus helicase, with EC50 values in the subnanomolar range for Yellow Fever and submicromolar EC50 for Dengue Fever, Japanese encephalitis, and tick-borne encephalitis viruses. However ivermectin is hampered in its application by pharmacokinetic problems (little solubility and high cytotoxicity). To overcome such problems we engineered different compositions of liposomes as ivermectin carriers characterizing and testing them on several cell lines for cytotoxicity. The engineered liposomes were less cytotoxic than ivermectin alone and they showed a significant increase of the antiviral activity in all the Dengue stains tested (1, 2, and S221). In the current study ivermectin is confirmed to be an effective potential antiviral and liposomes, as drug carriers, are shown to modulate the drug activity. All together the results represent a promising starting point for future improvement of ivermectin as antiviral and its delivery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.